Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection. Workshop in dendritic cell-based vaccine clinical trials in HIV-1

Vaccine

Volumn 29, Issue 38, 2011, Pages 6454-6463

  García, Felipe ^a   Routy, Jean Pierre ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Dendritic cells; HIV; Therapeutic vaccine

Indexed keywords

CD40 LIGAND; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MESSENGER RNA; NANOPARTICLE; NEF PROTEIN; PROTEIN P55; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; VPR PROTEIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DRUG DELIVERY SYSTEM; ELECTROPORATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY; VIRUS INACTIVATION; VIRUS LOAD; VIRUS RECOMBINANT;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY;

EID: 80051668754     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.043     Document Type: Review

References (76)

1. Carcelain G., Debre P., Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001, 13:483-488.
2. Blankson J.N., Persaud D., Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002, 53:557-593.
3. Ogg G., Bonhoeffer S., Dunbar R., Nowak M.A., Monard S., Segal G.P., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
4. Pitcher C., Quittner C., Peterson D., Connors M., Koup R.A., Maino V.C., et al. HIV-1 specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999, 5:518-525.
5. Letvin N.L., Walker B.D. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 2003, 9:861-866.
6. Plana M., Garcia F., Gallart M.T., Miro J.M., Gatell J.M. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet 1998, 352:1194-1195.
7. Garcia F., Plana M., Vidal C., Cruceta A., O'Brien W., Pantaleo G., et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999, 13:F79-F86.
8. Carcelain G., Tubiana R., Samri A., Calvez V., Delaugerre C., Agut H., et al. Transient mobilization of human immunodeciency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001, 75:234-241.
9. Martinez E., Mocroft A., García-Viejo M., Pérez-Cuevas J., Blanco J., Mallolas J., et al. A prospective cohort study on the risk for lipodystrophy in HIV-1 infected patients treated with protease inhibitor-containing regimens. Lancet 2001, 357:592-598.
10. Hel Z., Nacsa J., Tryniszewska E., Tsai W.P., Parks R.W., Montefiori D.C., et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 2002, 169:4778-4787.
11. Ostrowski M.A., Justement S.J., Ehler L.A., Mizell S.B., Lui S., Mican J., et al. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion ofHIV-1-specific memory cytotoxic CD8+ T cell responses. J Immunol 2000, 165:6133-6141.
12. Day C., Walker B.D. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 2003, 198:1773-1777.
13. Kaech S.M., Ahmed R. Immunology. CD8 T cells remember with a little help. Science 2003, 300:263-265.
14. Yokomaku Y., Miura H., Tomiyama H., Kawana-Tachikawa A., Takiguchi M., Kojima A., et al. Impaired processing and presentation of CTL epitopes are major escape mechanisms from CTL immune pressure in Human Immunodeficiency Virus type 1 infection. J Virol 2004, 78:1324-1332.
15. Seder R., Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003, 4:835-842.
16. Yang O., Sarkis P., Trocha A., Kalams S.A., Johnson R.P., Walker B.D. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol 2003, 171:3718-3724.
17. Donaghy H., Gazzard B., Gotch F., Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003, 101:4505-4511.
18. Chehimi J., Campbell D.E., Azzoni L., Bacheller D., Papasavvas E., Jerandi G., et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002, 168:4796-4801.
19. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109:1519-1526.
20. Kawamura T., Gatanaga H., Borris D.L., Connors M., Mitsuya H., Blauvelt A. Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. J Immunol 2003, 170:4260-4266.
21. Granelli-Piperno A., Golebiowska A., Trumpfheller C., Siegal F.P., Steinman R.M. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci USA 2004, 101:7669-7674.
22. Steinman R.M., Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002, 99:351-358.
23. Autran B., Debre B., Walker B.D., Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat Rev Immunol 2003, 3:503-508.
24. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
25. Banchereau J., Caux C., Davoust J., Lebecque S., Liu Y., Pulendran B., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
26. Larsson M., Fonteneau J., Bhardwaj N. Cross-presentation of cell-associated antigens by dendritic cells. Curr Top Microbiol Immunol 2003, 276:261-275.
27. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179:1109-1118.
28. Trepiakas R., Berntsen A., Hadrup S.R., Bjorn J., Geertsen P.F., Straten P.T., et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 2010, 12:721-734.
29. Lapenta C., Santini S., Logozzi M., Spada M., Andreotti M., Pucchio T., et al. Potent Immune responses against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 2003, 198:361-367.
30. Yoshida A., Tanaka R., Murakami T., Takahashi Y., Koyanagi Y., Nakamura M., et al. Induction of protective immune responses against R5 Human Immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intraesplenic immunization with HIV-1 pulsed dendritic cells: possible involvement of a novel factor of human CD4+ T-cell origin. J Virol 2003, 77:8719-8728.
31. Aline F., Brand D., Bout D., Pierre J., Fouquenet D., Verrier B., et al. Generation of specific Th1 and CD8+ T-cell responses by immunization with mouse CD8+ dendritic cells loaded with HIV-1 viral lysate or envelope glycoproteins. Microbes Infect 2007, 9:536-543.
32. Lu W., Wu X., Lu Y., Guo W., Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003, 9:27-32.
33. Kundu S.K., Engleman E., Benike C., Shapero M.H., Dupuis M., van Schooten W.C., et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998, 14:551-560.
34. Lu W., Arraes L., Ferreira W., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004, 10:1359-1365.
35. García F., Lejeune M., Climent N., Gil C., Alcami J., Morente V., et al. Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients. J Infect Dis 2005, 195:1680-1685.
36. Ide F., Nakamura T., Tomizawa M., Kawana-Tachikawa A., Odawara T., Hosoya N., et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006, 78:711-718.
37. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008, 15:284-292.
38. Gandhi R.T., O'Neill D., Bosch R.J., Chan E.S., Bucy R.P., Shopis J., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27:6088-6094.
39. Kloverpris H., Karlsson I., Bonde J., Thorn M., Vinner L., Pedersen A.E., et al. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009, 23:1329-1340.
40. Routy J.P., Boulassel M.R., Yassine-Diab B., Nicolette C., Healey D., Jain R., et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010, 134:140-147.
41. Garcia F., Climent N., Assoumou L., Gil C., Gonzalez N., Alcami J., et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011, 203:473-478.
42. Routy J.P., Angel J., Vezina S., Tremblay C., Loutfy M., Gill J., et al. Final Analysis of a Phase 2 Study of an Autologous DC Immunotherapy (AGS-004) Showed Positive Outcomes in Primary Endpoint of Viral Load Control, and Favorable Safety and Immunogenicity Profile, in Subjects Undergoing Structured Treatment Interruption of ART (Abstract 385). 18th Conference on Retroviruses and Opportunistic Infections 2011.
43. Rinaldo C.R. Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med 2009, 265:138-158.
44. Oshiro T.M., de A.A., da Silva Duarte A.J. Dendritic cell immunotherapy for HIV infection: from theory to reality. Immunotherapy 2009, 1:1039-1051.
45. Van G.E., Van Tendeloo V.F., Berneman Z.N., Vanham G. Role of dendritic cells in HIV-immunotherapy. Curr HIV Res 2010, 8:310-322.
46. Whiteside T.L., Piazza P., Reiter A., Stanson J., Connolly N.C., Rinaldo C.R., et al. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2009, 16:233-240.
47. Lu W., Andrieu J.M. In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol 2001, 75:8949-8956.
48. Gil C., Climent N., García F., Hurtado C., Nieto-Márquez S., Leon A., et al. Ex-vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. Vaccine 2011, 29:5711-5724.
49. Aline F., Brand D., Bout D., Pierre J., Fouquenet D., Verrier B., et al. Generation of specific Th1 and CD8+ T-cell responses by immunization with mouse CD8+ dendritic cells loaded with HIV-1 viral lysate or envelope glycoproteins. Microbes Infect 2007, 9:536-543.
50. Huang X.L., Fan Z., Zheng L., Borowski L., Li H., Thomas E.K., et al. Priming of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins. J Infect Dis 2003, 187:315-319.
51. Connolly N., Riddler S., Stanson J., Gooding W., Rinaldo C.R., Ferrone S., et al. Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects. AIDS 2007, 21:1683-1692.
52. Colleton B.A., Huang X.L., Melhem N.M., Fan Z., Borowski L., Rappocciolo G., et al. Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells. J Virol 2009, 83:6288-6299.
53. Huang X.L., Fan Z., Colleton B.A., Buchli R., Li H., Hildebrand W.H., et al. Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons. J Virol 2005, 79:3052-3062.
54. Chassin D., Andrieu M., Cohen W., Culmann-Penciolelli B., Ostankovitch M., Hanau D., et al. Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects. Eur J Immunol 1999, 29:196-202.
55. Van Gulck E.R., Ponsaerts P., Heyndrickx L., Vereecken K., Moerman F., De R.A., et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 2006, 107:1818-1827.
56. Van Gulck E.R., Vanham G., Heyndrickx L., Coppens S., Vereecken K., Atkinson D., et al. Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals. J Virol 2008, 82:3561-3573.
57. Kavanagh D.G., Kaufmann D.E., Sunderji S., Frahm N., Le G.S., Boczkowski D., et al. Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood 2006, 107:1963-1969.
58. Routy J.P., Boulassel M.R., Yassine-Diab B., Nicolette C., Healey D., Jain R., et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010, 134:140-147.
59. Weissman D., Ni H., Scales D., Dude A., Capodici J., McGibney K., et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 2000, 165:4710-4717.
60. Allard S.D., Pletinckx K., Breckpot K., Heirman C., Bonehill A., Michiels A., et al. Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. Vaccine 2008, 26:3735-3741.
61. Guerra S., Gonzalez J.M., Climent N., Reyburn H., Lopez-Fernandez L.A., Najera J.L., et al. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol 2010, 84:8141-8152.
62. Guerra S., Najera J.L., Gonzalez J.M., Lopez-Fernandez L.A., Climent N., Gatell J.M., et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 2007, 81:8707-8721.
63. Engelmayer J., Larsson M., Lee A., Lee M., Cox W.I., Steinman R.M., et al. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol 2001, 75:2142-2153.
64. Climent N., Guerra S., García F., Rovira C., Miralles L., Gómez C., et al. Dendritic cells exposed with MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8+ T cell response in HIV-1-infected individuals. Plos One 2011, 6:e19644.
65. Pion M., Serramia M.J., Diaz L., Bryszewska M., Gallart T., Garcia F., et al. Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials 2010, 31:8749-8758.
66. Aline F., Brand D., Pierre J., Roingeard P., Severine M., Verrier B., et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 2009, 27:5284-5291.
67. Gruber A., Chalmers A.S., Rasmussen R.A., Ong H., Popov S., Andersen J., et al. Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol 2007, 20:160-169.
68. *0201 mice. APMIS 2009, 117:849-855.
69. Lopez A., van der Lubbe N., Sanchez-Palomino S., Arnedo M., Nomdedeu M., Castro P., et al. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine 2009, 27:6166-6178.
70. Macatangay B.J., Szajnik M.E., Whiteside T.L., Riddler S.A., Rinaldo C.R. Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 2010, 5:e9852.
71. Ruiz A., Nomdedeu M., Ortega M., Lejeune M., Setoain J., Climent N., et al. Assessment of migration of HIV-1 loaded dendritic cells labelled with 111In-oxine used as a therapeutic vaccine in HIV-1 infected patients. Immunotherapy 2009, 1:347-354.
72. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., Lyerly H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999, 59:56-58.
73. Frank I., Santos J.J., Mehlhop E., Villamide-Herrera L., Santisteban C., Gettie A., et al. Presentation of exogenous whole inactivated simian immunodeficiency virus by mature dendritic cells induces CD4+ and CD8+ T-cell responses. J Acquir Immune Defic Syndr 2003, 34:7-19.
74. Larsson M., Fonteneau J., Lirvall M., Haslett P., Lifson J.D., Bhardwaj N. Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS 2002, 16:1319-1329.
75. Rossio J.L., Esser M.T., Suryanarayana K., Schneider D.K., Bess J.W., Vasquez G.M., et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998, 72:7992-8001.
76. Montes M., Loof N., Cobb A., King B., Sloan L., Harrod C., et al. Immunization with Dendritic cells loaded with HIV-derived lipopeptides expand HIV-specific CD4+ T cells in HIV infected patients under HAART (Abstract P18.09). AIDS Vaccine 2010 Conference 2010.